Rigel Pharmaceuticals, Inc. (RIGL)
Automate Your Wheel Strategy on RIGL
With Tiblio's Option Bot, you can configure your own wheel strategy including RIGL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RIGL
- Rev/Share 11.4037
- Book/Share 1.0426
- PB 17.9356
- Debt/Equity 3.289
- CurrentRatio 2.1997
- ROIC 0.3438
- MktCap 334213880.0
- FreeCF/Share 2.0043
- PFCF 9.3636
- PE 8.9572
- Debt/Assets 0.347
- DivYield 0
- ROE -6.5526
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 3
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Is Rigel Pharmaceuticals (RIGL) Stock Undervalued Right Now?
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Wall Street Analysts See a 71.97% Upside in Rigel (RIGL): Can the Stock Really Move This High?
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 72% upside potential for Rigel (RIGL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress
Published: May 22, 2025 by: PRNewsWire
Sentiment: Neutral
Final data from the GAVRETO® (pralsetinib) Phase 1/2 ARROW study in RET fusion-positive NSCLC and other solid tumors Supportive data for REZLIDHIA® (olutasidenib) utilization in patients with mIDH1 R/R AML SOUTH SAN FRANCISCO, Calif. , May 22, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced seven upcoming poster presentations at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) 2025 Congress.
Read More
Here's Why Rigel (RIGL) Is a Great 'Buy the Bottom' Stock Now
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Rigel (RIGL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Read More
Is Rigel Pharmaceuticals (RIGL) a Great Value Stock Right Now?
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Earnings Estimates Rising for Rigel (RIGL): Will It Gain?
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Rigel (RIGL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Read More
Wall Street Analysts Think Rigel (RIGL) Could Surge 82.3%: Read This Before Placing a Bet
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Rigel (RIGL) points to an 82.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Rigel Pharmaceuticals: Q1 Earnings Showcase Growing Momentum
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Positive
Rigel Pharmaceuticals, Inc. shows strong momentum, with a 68% YoY revenue increase, driven by TAVALISSE, GAVRETO, and REZLIDHIA, suggesting a shift to a durable growth stock. Q1 net income of $11.4M and improved gross margins highlight Rigel's operating leverage, reducing the need for dilutive fundraising and supporting future R&D investments. R289's promising pipeline progress and TAVALISSE's patent extension to 2032 bolster Rigel's long-term outlook, despite reliance on key products and competitive markets.
Read More
Rigel Pharmaceuticals, Inc. (RIGL) Q1 2025 Earnings Call Transcript
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Ray Furey - Executive Vice President, General Counsel & Corporate Secretary. Raul Rodriguez - President & Chief Executive Officer Dave Santos - Chief Commercial Officer Lisa Rojkjaer - Chief Medical Officer Dean Schorno - Chief Financial Officer Conference Call Participants Kalpit Patel - B.
Read More
Rigel Pharmaceuticals (RIGL) Beats Q1 Earnings and Revenue Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to loss of $0.50 per share a year ago.
Read More
Rigel (RIGL) Upgraded to Buy: What Does It Mean for the Stock?
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Rigel (RIGL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
4 Healthcare Stocks to Buy as the Sector Faces Government Heat
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the Trump administration's healthcare policies.
Read More
Wall Street Analysts Believe Rigel (RIGL) Could Rally 44.93%: Here's is How to Trade
Published: March 05, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Rigel (RIGL) points to a 44.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Rigel Pharmaceuticals (RIGL) Surpasses Q4 Earnings and Revenue Estimates
Published: March 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.80 per share, beating the Zacks Consensus Estimate of $0.55 per share. This compares to break-even earnings per share a year ago.
Read More
Should You Add RIGL Stock to Your Portfolio Pre-Q4 Earnings?
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Rigel Pharmaceuticals has put up a strong performance in 2024 and should maintain momentum in 2025. Irrespective of how the company fares in Q4, we recommend investors to add the stock to their portfolio.
Read More
RIGL Stock Surges 41.4% in a Year: Time to Buy or Sell?
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Rigel Pharmaceuticals has put up a strong performance in 2024 and should maintain momentum in 2025. We believe there is more room for growth.
Read More
About Rigel Pharmaceuticals, Inc. (RIGL)
- IPO Date 2000-11-29
- Website https://www.rigel.com
- Industry Biotechnology
- CEO Raul R. Rodriguez
- Employees 162